

# Biomarkers for early sepsis detection

Bettina Leber, PhD,<sup>1,2\*</sup> Angela Horvath, PhD,<sup>1,2\*</sup> Irina Komarova,<sup>3</sup> MD, Bianca Schmerboeck, BSc,<sup>1,2</sup> Ingeborg Klymiuk, PhD,<sup>4</sup> Marija Durdevic, MSc,<sup>5</sup> Florian Rainer<sup>3</sup>, MD, Andreas Blesl<sup>3</sup>, MD, Philipp Stiegler, MD,<sup>1</sup> Vanessa Stadlbauer, MD,<sup>3</sup>

<sup>1</sup>Department of Transplantation Surgery, Medical University of Graz, Austria, <sup>2</sup>Center for Biomarker Research in Medicine (CBmed), Austria, <sup>3</sup>Department of Gastroenterology and Hepatology, Medical University of Graz, Austria, <sup>4</sup>Center for Medical Research, Core Facility Molecular Biology, Medical University of Graz, Austria. <sup>5</sup>Core Facility Computational Bioanalytics, Medical University of Graz, Austria

## Introduction

- Sepsis
  - Systemic, deleterious host response to infection
  - affects millions of people around the world each year, lethality of 25%-50%
- therapeutic goal: "Hit early, hit fast, hit hard(right)"
- loss of gut wall integrity: pivotal role
- gut microbiome composition: important mechanism
- no data on gut barrier function and gut microbiome composition in early sepsis available


## Aims

- identification of potential biomarkers for early sepsis
- proof of concept: effects of a multispecies probiotic on gut microbiota and gut wall integrity

## Methods

- Pilot clinical trial on patients with early sepsis receiving a multispecies probiotic (Winlove 607) or placebo for 28 days
- Gut microbiome in stool samples (16s sequencing, bioinformatics)
- Markers of gut wall integrity (fecal zonulin and calprotectin, serum diamino oxidase)
- Markers of bacterial translocation (LPS, sCD14, LBP, peptidoglykane, bacterial DNA)
- Methods: ELISA, HEK-Blue reporter cells


## Enrolment and patient characteristics



	Early sepsis (n=15*)	Healthy controls (n=21)
Age (years)	54 +/- 17	58 +/- 7
Gender female/male	7/8	12/9
BMI kg/m <sup>2</sup>	26 +/- 5	25 +/- 3
White blood cells	12.7 +/- 9.1**	5.6 +/- 1.8
CRP	160.3 +/- 124.9***	2.1 +/- 2.2

The reasons for dropout were diarrhoea (n=1, placebo group), nausea (n=3, 2 placebo, 1 probiotic) and withdrawal of consent before the first dose of the study product was taken (n=2, both probiotic). Dropouts were therefore not related to the intervention.

## Microbiome composition and function in early sepsis




- Early sepsis is associated with
  - decreased alpha diversity and beta diversity of the gut microbiome
  - Loss of beneficial species
  - Decreased functional content

## Gut permeability and bacterial translocation in early sepsis

	baseline	day 7	day 28	Healthy controls
Calprotectin in stool (ng/ml)	191 (45; 568)	44 (32; 621)	62 (26; 199)	56 (27; 80)
Zonulin in stool (ng/ml)	49 (17; 96)	74 (30; 116)	57 (54; 193)	66 (57; 79)
DAO (U/ml)	11 (7; 23)	9 (7; 14)	7 (5; 10)	9 (8; 15)
Endotoxin (EU/ml)	4 (1.5; 1)**	5 (1; 41)*	3 (1; 6)*	2 (1; 3)
sCD14 (pg/ml)	2.8 (2.1; 3.6)***	2.2 (1.6; 3.6)*	2.2 (1.6; 3.2)*	1.7 (1.5; 1.8)
LBP (ng/ml)	39 (30; 62)***	23 (15; 31)	13 (9; 16)	17 (15; 21)
Bacterial DNA (cpM)	17 (11; 19)	12 (10; 30)	13 (10; 19)	10 (7; 18)
Peptidoglycane (ng/ml)	1.8 (1.4; 2.7)	1.6 (1.0; 2.4)	1.6 (1.3; 2.3)	0.8 (0.5; 1.1)

- Early sepsis is associated with
  - Increased endotoxin and endotoxin binding proteins
  - No changes in gut barrier function

## Effect of Winlove 607 on the gut microbiome in early sepsis



- Probiotic modulation
  - Increases functional diversity
  - Increases abundance of probiotic strains

## Conclusions

- Sepsis is associated with early structural and functional changes in microbiome composition
- Alpha Diversity may be a useful biomarker
- Gut permeability is not severely altered
- Probiotic modulation of the gut microbiome is feasible in early sepsis

## Acknowledgments

Work done in "CBmed" was funded by the Austrian Federal Government within the COMET K1 Centre Program, Land Steiermark and Land Wien.

## CONTACT

- CBmed GmbH
- CENTER FOR BIOMARKER RESEARCH
- IN MEDICINE
- Stiftingtalstrasse 5, 8010 Graz
- Phone: +43 316 385 28801
- office@cbmed.at